On September 22, 2020 Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, reported that it has won the "Best ADC Platform Technology" category at the 2020 World ADC Awards ceremony (Press release, Synaffix, SEP 22, 2020, View Source [SID1234565463]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Synaffix’ ADC platform consists of GlycoConnect, HydraSpace and toxSYN which comprise site-specific technology and payloads to enable best-in-class ADCs.

Synaffix was presented the award during the 2020 World ADC Digital event. The finalists were shortlisted through a voting pool of over 1,000 individuals, with a panel of distinguished, independent industry experts from across the ADC field, assessing each finalist to decide the winners.

The judging panel highlighted the following three cornerstone features of the Synaffix ADC platform:

Consistent delivery of highly competitive ADC product candidates
Strong commercial and scientific validation (over $420m in out-licensing deals,at least six ADCs in development with two in clinical trials)
Compatible and easy to use with any antibody